Mymd Pharmaceuticals (QCLS) Stock Price, News & Analysis

Company Overview

MyMD Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation. MyMD Pharmaceuticals is based in the United States and has operated as a research-driven biotechnology company centered on bringing new therapeutic options to market.

Because company details can change over time and reliable, up-to-date information on leadership and current geographic operations is limited, this description is intentionally brief and limited to broadly verifiable business information.

Key Stats

• Today's Range: $4.28 to $4.90
• 50-Day Range: N/A
• 52-Week Range: $2.50 to $33.56
• Volume: 612,859 shs
• Average Volume: 571,102 shs
• Market Capitalization: $18.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Mymd Pharmaceuticals Stock Analysis - MarketRank™

Mymd Pharmaceuticals scored higher than 20% of companies evaluated by MarketBeat, and ranked 70th out of 81 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Mymd Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Mymd Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mymd Pharmaceuticals is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mymd Pharmaceuticals is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mymd Pharmaceuticals has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for QCLS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mymd Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Mymd Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.04

News Sentiment

Mymd Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Mymd Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

11 people have searched for QCLS on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.

MarketBeat Follows

1 people have added Mymd Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $5,522.00 in company stock, which represents 0.0306% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Mymd Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,522.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.86% of the stock of Mymd Pharmaceuticals is held by insiders.

Percentage Held by Institutions

9.64% of the stock of Mymd Pharmaceuticals is held by institutions.

Company Calendar

• Today: 5/15/2026
• Last Earnings: 5/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: In Vitro, In Vivo Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QCLS
• CIK: 1321834
• Web: N/A
• Phone: (856) 848-8698
• Fax: 856-848-0269
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($122.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -94.03%
• Return on Assets: -40.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.00
• Quick Ratio: 3.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.19 per share
• Price / Book: 0.83

Miscellaneous

• Outstanding Shares: 4,170,000
• Free Float: 4,131,000
• Market Cap: $18.06 million
• Optionable: N/A
• Beta: 2.11